Luigi Nocera
Luigi Nocera
Università Vita-Salute San Raffaele, Milan, Italy
Verified email at
Cited by
Cited by
Development and internal validation of a novel model to identify the candidates for extended pelvic lymph node dissection in prostate cancer
G Gandaglia, N Fossati, E Zaffuto, M Bandini, P Dell’Oglio, CA Bravi, ...
European urology 72 (4), 632-640, 2017
Robot-assisted radical prostatectomy with the novel Hugo robotic system: initial experience and optimal surgical set-up at a tertiary referral robotic center
CA Bravi, M Paciotti, L Sarchi, A Mottaran, L Nocera, R Farinha, ...
European urology 82 (2), 233-237, 2022
Surgical safety of radical cystectomy and pelvic lymph node dissection following neoadjuvant pembrolizumab in patients with bladder cancer: prospective assessment of …
A Briganti, G Gandaglia, S Scuderi, A Gallina, R Colombo, N Fossati, ...
European urology 77 (5), 576-580, 2020
Incidence and survival rates of contemporary patients with invasive upper tract urothelial carcinoma
CC Ruvolo, L Nocera, LF Stolzenbach, M Wenzel, V Cucchiara, Z Tian, ...
European urology oncology 4 (5), 792-801, 2021
Efficacy of local treatment in prostate cancer patients with clinically pelvic lymph node-positive disease at initial diagnosis
T Seisen, MW Vetterlein, P Karabon, T Jindal, A Sood, L Nocera, ...
European urology 73 (3), 452-461, 2018
Bladder cancer: a comparison between non-urothelial variant histology and urothelial carcinoma across all stages and treatment modalities
M Deuker, T Martin, F Stolzenbach, G Rosiello, CC Ruvolo, L Nocera, ...
Clinical Genitourinary Cancer 19 (1), 60-68. e1, 2021
Overall survival after systemic treatment in high-volume versus low-volume metastatic hormone-sensitive prostate cancer: systematic review and network meta-analysis
M Wenzel, C Würnschimmel, L Nocera, CC Ruvolo, Z Tian, SF Shariat, ...
European Urology Focus 8 (2), 399-408, 2022
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a …
M Wenzel, L Nocera, C Colla Ruvolo, C Würnschimmel, Z Tian, ...
Prostate cancer and prostatic diseases 25 (2), 139-148, 2022
Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial
G Basile, M Bandini, EA Gibb, JS Ross, D Raggi, L Marandino, ...
Clinical Cancer Research 28 (23), 5107-5114, 2022
Clinical outcomes and adverse events after first-line treatment in metastatic renal cell carcinoma: a systematic review and network meta-analysis
L Nocera, PI Karakiewicz, M Wenzel, Z Tian, SF Shariat, F Saad, ...
The Journal of Urology 207 (1), 16-24, 2022
Outcomes of robot-assisted radical prostatectomy with the Hugo RAS surgical system: initial experience at a high-volume robotic center
CA Bravi, M Paciotti, E Balestrazzi, A Piro, F Piramide, M Peraire, L Sarchi, ...
European Urology Focus 9 (4), 642-644, 2023
Upper urinary tract tumors: variant histology versus urothelial carcinoma
M Deuker, LF Stolzenbach, CC Ruvolo, L Nocera, Z Tian, FC Roos, ...
Clinical Genitourinary Cancer 19 (2), 117-124, 2021
Functional outcomes of clinically high-risk prostate cancer patients treated with robot-assisted radical prostatectomy: a multi-institutional analysis
F Abdollah, D Dalela, A Sood, J Sammon, R Cho, L Nocera, M Diaz, ...
Prostate cancer and prostatic diseases 20 (4), 395-400, 2017
Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups
C Würnschimmel, M Wenzel, C Colla Ruvolo, L Nocera, Z Tian, F Saad, ...
International Journal of Urology 28 (8), 862-869, 2021
Robot-assisted sacropexy with the novel HUGO robot-assisted surgery system: initial experience and surgical setup at a tertiary referral robotic center
A Mottaran, CA Bravi, L Sarchi, M Paciotti, L Nocera, A Piro, P Piazza, ...
Journal of Endourology 37 (1), 35-41, 2023
Increasing rates of NCCN high and very high‐risk prostate cancer versus number of prostate biopsy cores
M Wenzel, C Würnschimmel, CC Ruvolo, L Nocera, Z Tian, F Saad, ...
The prostate 81 (12), 874-881, 2021
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: a systematic review and meta-analysis
A Martini, D Raggi, G Fallara, L Nocera, JG Schultz, F Belladelli, ...
Cancer Treatment Reviews 104, 102360, 2022
Robot-assisted simple prostatectomy with the novel HUGO™ RAS System: feasibility, setting, and perioperative outcomes.
A Mottaran, M Paciotti, CA Bravi, L Sarchi, L Nocera, A Piro, R Farinha, ...
Minerva Urology and Nephrology, 2022
Incidence rates and contemporary trends in primary urethral cancer
M Wenzel, L Nocera, C Colla Ruvolo, C Würnschimmel, Z Tian, ...
Cancer Causes & Control 32, 627-634, 2021
Tumor size predicts muscle-invasive and non–organ-confined disease in upper tract urothelial carcinoma at radical nephroureterectomy
CC Ruvolo, L Nocera, LF Stolzenbach, M Wenzel, G Califano, Z Tian, ...
European Urology Focus 8 (2), 498-505, 2022
The system can't perform the operation now. Try again later.
Articles 1–20